Dr. Jamal Hammoud, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 738
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
MI license JH045812
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mclaren Flint Flint, MI
- Mclaren Lapeer Region Lapeer, MI
Medical groups
- Endocrine Consultants of Mid Michigan PC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 738
- Services billed
- 4,359
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 824 | 410 |
| Established patient office or other outpatient visit, 20-29 minutes | 743 | 485 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 667 | 132 |
| Hemoglobin a1c level, by device for home use | 620 | 336 |
| Blood glucose (sugar) level | 612 | 304 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 352 | 226 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 183 | 161 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 154 | 143 |
| Ultrasound scan of head and neck soft tissue | 147 | 137 |
| New patient office or other outpatient visit, 45-59 minutes | 129 | 129 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Flint, MI | 1,234 |
| Trulicity (dulaglutide) Other prescribers in Flint, MI | 886 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Flint, MI | 723 |
| Ozempic (semaglutide) Other prescribers in Flint, MI | 681 |
| Metformin Hcl Other prescribers in Flint, MI | 634 |
| Jardiance (empagliflozin) Other prescribers in Flint, MI | 621 |
| Mounjaro (tirzepatide) Other prescribers in Flint, MI | 490 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in Flint, MI | 357 |
| Glimepiride Other prescribers in Flint, MI | 239 |
| Novolog Flexpen (insulin aspart) Other prescribers in Flint, MI | 237 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 201 payments worth $41,689 in total to this clinician.
| Lilly USA, LLC | $33,095 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,309 |
| Novo Nordisk Inc | $2,964 |
| Amgen Inc. | $417 |
| Corcept Therapeutics | $312 |
| Beta Bionics, Inc. | $273 |
| Xeris Pharmaceuticals, Inc. | $223 |
| Abbott Laboratories | $170 |
| Compensation for services other than consulting (speaking, faculty) | $33,150 |
|---|---|
| Food and Beverage | $2,941 |
| Travel and Lodging | $2,809 |
| Consulting Fee | $2,790 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Feb 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,600 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Novo Nordisk Inc Oct 22, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,395 |
All 37 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Lilly USA, LLC Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Novo Nordisk Inc Oct 22, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,395 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,125 |
| Novo Nordisk Inc Oct 21, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,395 |
| Lilly USA, LLC Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Oct 20, 2025 | Travel and Lodging travel to BAY CITY, MI · in-kind | $706 |
| Lilly USA, LLC Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $800 |
| Lilly USA, LLC Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $900 |
| Lilly USA, LLC Jun 23, 2025 | Travel and Lodging MOUNJARO · Diabetes · travel to DAVISON, MI | $35.00 |
| Lilly USA, LLC Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $675 |
| Lilly USA, LLC Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,800 |
| Lilly USA, LLC Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes | $1,125 |
| Lilly USA, LLC Apr 17, 2025 | Travel and Lodging travel to DETROIT, MI · in-kind | $556 |
| Lilly USA, LLC Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $800 |
| Lilly USA, LLC Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $800 |
| Lilly USA, LLC Feb 28, 2025 | Travel and Lodging MOUNJARO · Diabetes · travel to ATLANTA, GA | $55.00 |
| Lilly USA, LLC Feb 19, 2025 | Compensation for services other than consulting (speaking, faculty) MOUNJARO · Diabetes Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,600 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $660 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, MI · in-kind | $365 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, MI · in-kind | $352 |
| Lilly USA, LLC Feb 6, 2025 | Travel and Lodging travel to ATLANTA, MI · in-kind | $79.69 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $543,571 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.